

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2011

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 31/12/2011	Previous Quarter ended 30/09/2011	Corresponding Quarter ended 31/12/2010	Twelve Months ended 31/12/2011	Twelve Months ended 31/12/2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	32,657.78	45,104.29	42,802.91	166,195.39	161,657.85
	b) Other Operating Income	184.34	226.38	338.19	930.78	1,063.76
	c) Total	32,842.12	45,330.67	43,141.10	167,126.17	162,721.61
2	Expenditure					
	a) (Increase)/decrease in stock in trade and work in progress	(10,993.18)	1,258.41	(204.23)	(14,836.69)	(9,332.32)
	b) Consumption of raw materials	29,610.80	25,022.59	20,700.59	102,839.71	89,387.90
	c) Employees Cost	1,332.87	1,327.73	1,164.23	5,056.56	4,371.50
	d) Depreciation	6,186.58	6,143.40	7,183.08	25,117.80	19,762.17
	e) Other expenditure	2,463.52	2,671.39	1,948.64	9,435.24	7,522.53
	f) Total	28,600.59	36,423.52	30,792.31	127,612.62	111,711.78
3	Profit / (Loss) from Operations before Other Income and Interest (1-2)	4,241.53	8,907.15	12,348.79	39,513.55	51,009.83
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) before Interest (3+4)	4,241.53	8,907.15	12,348.79	39,513.55	51,009.83
6	Interest	7,267.12	7,184.38	6,218.32	27,043.08	23,047.05
7	Profit / (Loss) from Ordinary Activities before tax (5-6)	(3,025.59)	1,722.77	6,130.47	12,470.47	27,962.78
8	Tax expense					
	a) Current	(2,244.15)	320.18	550.00	571.70	4,020.00
	b) Deferred	(1,561.89)	208.12	450.00	354.41	3,100.00
	c) Total	(3,806.04)	528.30	1,000.00	926.11	7,120.00
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	780.45	1,194.47	5,130.47	11,544.36	20,842.78
10	Extraordinary Items	(8,195.16)	(121.87)	(2,836.00)	(9,622.71)	(6,310.48)
11	Net Profit / (Loss) for the period (9+10)	(7,414.71)	1,072.60	2,294.47	1,921.65	14,532.30
12	Prior year adjustment	0.00	0.00	0.00	0.00	88.39
13	Profit available for appropriation	(7,414.71)	1,072.60	2,294.47	1,921.65	14,620.69
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet.					244,415.28
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.					
	Basic	0.29	0.45	1.92	4.31	8.16
	Diluted	0.26	0.39	1.70	3.82	7.19
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.					
	Basic	(2.77)	0.40	0.86	0.72	5.69
	Diluted	(2.45)	0.35	0.76	0.64	5.01
17	Public Shareholding					
	- Number of shares	131,861,090	133,240,656	133,666,531	131,861,090	133,666,531
	- Percentage of shareholding	49.23%	49.74%	49.90%	49.23%	49.90%

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2011

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 31/12/2011	Previous Quarter ended 30/09/2011	Corresponding Quarter ended 31/12/2010	Twelve Months ended 31/12/2011	Twelve Months ended 31/12/2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	50,816,835	75,777,817	18,228,340	50,816,835	18,228,340
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.94%	84.71%	20.47%	55.94%	20.47%
	Percentage of shares (as a % of the total share capital of the Company)	18.97%	28.29%	6.80%	18.97%	6.80%
	b) Non-encumbered					
	Number of shares	40,023,300	13,682,752	70,806,354	40,023,300	70,806,354
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.06%	15.29%	79.53%	44.06%	79.53%
	Percentage of shares (as a % of the total share capital of the Company)	14.94%	5.11%	26.43%	14.94%	26.43%

Notes:

1 Statement of Assets and Liabilities

(Rs. in Lacs)

Sr. No.	Particulars	TWELVE Months Ended 31/12/2011	Corresponding TWELVE Months Ended 31/12/2010
		Unaudited	Audited
1	SHAREHOLDERS' FUNDS		
	a) Capital	2,678.74	2,678.74
	b) Reserves and Surplus	246,336.93	244,415.28
2	LOAN FUNDS	426,099.51	374,383.99
3	Deferred Tax Liability	31,536.41	31,182.00
	TOTAL	706,651.59	652,660.01
4	FIXED ASSETS	459,274.82	410,766.02
5	INVESTMENTS	36,500.33	36,392.91
6	CURRENT ASSETS, LOANS AND ADVANCES		
	a) Inventories	100,879.01	68,551.04
	b) Sundry Debtors	72,301.17	67,641.02
	c) Cash and Bank Balances	2,059.28	15,837.21
	d) Loans and Advances	42,685.17	64,953.65
	Less: Current Liabilities and Provisions		
	a) Liabilities	6,598.36	6,504.21
	b) Provisions	571.70	5,586.99
7	MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	121.87	609.36
	TOTAL	706,651.59	652,660.01

2 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.

3 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 14 February 2012.

4 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31 December 2011.

5 The Company has Overseas Subsidiary namely Sterling Fincom Pvt. Ltd., Mauritius and there are no business operations in the said subsidiary company.

6 The number of investor complaints for the quarter ended on 31 December 2011 were :
Opening - NIL, Received - 04, Disposed off - 04, and Balance - NIL.

7 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of
STERLING BIOTECH LIMITED**

Place : Mumbai
Date : 14 February 2012.

**Chetan J. Sandesara
Joint Managing Director**